


TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER TPIP017D/WO US U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <div style="font-size: 2em; font-weight: bold; margin-top: 5px;">10/541216</div>
INTERNATIONAL APPLICATION NO. PCT/US2003/041273	INTERNATIONAL FILING DATE 24 December 2003	PRIORITY DATE CLAIMED 30 December 2002
TITLE OF INVENTION PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION		
APPLICANT(S) FOR DO/EO/US M. Tawa, J. Remenar, M. Peterson, O. Almarsson, H. Guzman, H. Chen, M. Oliveira		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A preliminary amendment. 14. <input checked="" type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input checked="" type="checkbox"/> A power of attorney and/or change of address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: Petition to Submit Color Drawings; return postcard 		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/541216		INTERNATIONAL APPLICATION NO. PCT/US2003/041273		ATTORNEY'S DOCKET NUMBER TPIP017D/WO US	
The following fees have been submitted				CALCULATIONS PTO USE ONLY	
21. <input checked="" type="checkbox"/> Basic national fee..... \$300				\$ 300.00	
22. <input checked="" type="checkbox"/> Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)..... \$100 All other situations..... \$200				\$ 200.00	
23. <input checked="" type="checkbox"/> Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority..... \$100 International Search Report prepared and provided to the Office..... \$400 All other situations..... \$500				\$ 100.00	
TOTAL OF 21, 22 and 23 =				\$ 600.00	
<input checked="" type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
258 - 100 =	158 /50 =	4	x \$250	\$ 1,000.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	29 - 20 =	9	x \$ 50	\$ 450.00	
Independent claims	2 - 3 =	0	x \$200	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 2,050.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.					
SUBTOTAL =				\$ 2,050.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				\$	
TOTAL NATIONAL FEE =				\$ 2,050.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$ 2,050.00	
				Amount to be refunded:	\$
				Amount to be charged:	\$
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>502626</u> in the amount of \$ <u>2,050.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>502626</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>					
<p>NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.</p>					
<p>SEND ALL CORRESPONDENCE TO: TransForm Pharmaceuticals, Inc. 29 Hartwell Avenue Lexington, MA 02421</p>					
				<p> SIGNATURE Paul Burgess NAME 53,852 REGISTRATION NUMBER</p>	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Mark Tawa et al.

Serial No.: Not Yet Assigned

Group No.:

Filed: Herewith

Examiner:

For: PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION

Attorney Docket Number: TPIP017DWO US

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION TO SUBMIT COLOR DRAWINGS

Sir:


Applicants hereby petition, in accordance with 37 CFR 1.84(a)(2), for the submission of color drawings for Figures 95, 99 and 100. Color drawings are necessary for these figures as they are the only useful means by which to disclose the desired subject matter of the patent application. Applicants have enclosed three (3) sets of color drawings for each of Figures 95, 99 and 100, as well as a black and white copy of each of Figures 95, 99 and 100, which accurately depicts, to the extent possible, the subject matter as shown in each of the color drawings.

In addition, Applicants have also submitted a Preliminary Amendment (separately attached) which provides for an amendment to the specification to insert the following required language as the first paragraph of the brief description of the drawings:

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

The Commissioner is hereby authorized to charge the required petition fee of \$130.00 as set forth in 1.17(h), and any additional fees or underpayments of fees, or credit any overpayment, to Deposit Account No. 50-2626.

Dated: June 29, 2005

Respectfully submitted,
By: 
Paul Burgess, Attorney for Applicants
Registration Number 53,852
TransForm Pharmaceuticals, Inc.
29 Hartwell Avenue
Lexington, MA 02421
Phone: 781-674-7816 Fax: 781-863-7208

JC14 Rec'd PCT/PTO 29 JUN 2005

PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION

Inventors: Mark Tawa
16 Carol Circle
West Roxbury, MA 02132
Citizenship: USA

Julius Remenar
9 Eaton Road
Framingham, MA 01701
Citizenship: USA

Matthew Peterson
25 Downey Street
Hopkinton, MA 01748
Citizenship: USA

Orn Almarsson
22 Farmington Drive
Shrewsbury, MA 01545
Citizenship: Iceland


Hector Guzman
47 Wyman Street
Jamaica Plain, MA 02130
Citizenship: USA

Hongming Chen
8 Sawmill Road
Acton, MA 01720
Citizenship: China

Mark Oliveira
69 Nicholas Road, Apt. J
Framingham, MA 01701
Citizenship: USA

CERTIFICATE OF MAILING BY EXPRESS MAIL UNDER 37 CFR 1.10

I hereby certify that the attached *Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Submission Under 35 U.S.C. 371*, and any attachments referred to therein, are being deposited with the United States Postal Service on this date June 29, 2005 in an envelope as "Express Mail Post Office to Addressee", mailing Label Number EV457099578 US addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Kristin Miele